Publication | Closed Access

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062

OncologySingle AgentMedicineMetronomic TherapyPhase Ii StudyBronchial NeoplasmCisplatin Versus CisplatinCancer TreatmentPharmacologyRadiation OncologyLung Cancer